Posted in | News | Mining Business | Alumina

Production Activities Continue to Progress Positively at Orbite's High Purity Alumina Plant

Orbite Technologies Inc. (TSX: ORT) (OTCQX: EORBF) ("Orbite", or the "Company") today announced that, further to its press release of November 11, 2016, production activities continue to progress positively at its high purity alumina ("HPA") plant.

  • As reported on November 11, feedstock digestion continues to operate automatically and smoothly, and digestion liquors continue to be transferred to the crystallisation circuit for the production of aluminum chloride hexahydrate ("ACH") crystals, the precursor to HPA.
  • In preparation for the calcination of the produced ACH into HPA, the Company continues to produce amorphous HPA to constitute the initial 'bed' in the fluidized bed decomposer and calciner. This HPA is produced using the Company's legacy low-capacity Harper decomposer and production of the bed material continues to progress positively.
  • The heating up sequence of the decomposer and calciner reactors has commenced and is progressing well. Accordingly, the Company anticipates introducing the required quantity of bed material into the new calcination system soon, which will be followed by the calcination of ACH into HPA.

"We continue to progress towards calcination of the produced ACH into HPA and will be commencing this final production step soon," stated Glenn Kelly, CEO of Orbite. "While the production of the amorphous HPA takes time due to the low capacity nature of the Harper equipment, the HPA process and its different systems continue to perform well. Based on our progress to date, we are confident of being a commercial producer of 5N+ HPA soon."

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.